| Name | Title | Contact Details |
|---|---|---|
Keleigh Pearson |
Assistant General Counsel - NABU | Profile |
Jeff Gold |
Chief IP Counsel | Profile |
Rachel Lei |
General Counsel and Corporate Secretary | Profile |
Kenneth Bonnell |
Vice President of Quality and Regulatory Affairs | Profile |
ATS Scientific Inc. is a Burlington, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Accurate Automation Corp. is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.
Biofourmis is a fast-growing global health IT start-up founded in Singapore that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. The company discovers, develops and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized artificial intelligence (AI)-powered health analytics platform that predicts clinical exacerbation days in advance before a critical event. Biovitals™ is the backbone of the company`s Digital Therapeutics product pipeline, which spans a number of therapeutic areas and disease states, including heart failure, acute coronary syndrome, COPD and chronic pain.
Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor`s lead product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI marketing application in the European Union in the second half of 2013. Raptor’s product pipeline may advance therapeutic options for additional indications. Raptor`s management team consists of repeat entrepreneurs with the experience to build a successful company.